Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

Abstract	The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 16 (4%); efavirenz/tenofovir/emtricitabine arm, 58 (14%)] through W144 [corrected]. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144.
Authors	Sharon Walmsley, Axel Baumgarten, Juan Berenguer, Franco Felizarta, Eric Florence, Marie-Aude Khuong-Josses, J Michael Kilby, Thomas Lutz, Daniel Podzamczer, Joaquin Portilla, Norman Roth, Deborah Wong, Catherine Granier, Brian Wynne, Keith Pappa
Journal	Journal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 70 Issue 5 Pg. 515-9 (Dec 15 2015) ISSN: 1944-7884 [Electronic] United States
PMID	26262777 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Anti-HIV Agents Dideoxynucleosides Drug Combinations Heterocyclic Compounds, 3-Ring Oxazines Piperazines Pyridones abacavir, lamivudine drug combination Lamivudine dolutegravir
Topics	Anti-HIV Agents (administration & dosage, therapeutic use) Dideoxynucleosides (administration & dosage, therapeutic use) Double-Blind Method Drug Administration Schedule Drug Combinations Drug Therapy, Combination HIV Infections (drug therapy) HIV-1 Heterocyclic Compounds, 3-Ring (administration & dosage, therapeutic use) Humans Lamivudine (administration & dosage, therapeutic use) Oxazines Piperazines Pyridones

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!